Overview

A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine

Status:
Terminated

Trial end date:
2009-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether CG5503 (tapentadol) is effective and safe in the treatment of chronic tumor related pain compared to placebo.

Phase:

Phase 3

Details

Lead Sponsor:

Grünenthal GmbH

Collaborator:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Treatments:

Morphine
Tapentadol